SG11201510251TA - Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase - Google Patents
Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenaseInfo
- Publication number
- SG11201510251TA SG11201510251TA SG11201510251TA SG11201510251TA SG11201510251TA SG 11201510251T A SG11201510251T A SG 11201510251TA SG 11201510251T A SG11201510251T A SG 11201510251TA SG 11201510251T A SG11201510251T A SG 11201510251TA SG 11201510251T A SG11201510251T A SG 11201510251TA
- Authority
- SG
- Singapore
- Prior art keywords
- estratrienthiazole
- inhibitors
- beta
- derivatives
- therapeutically active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0052—Nitrogen only at position 16(17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20135694 | 2013-06-25 | ||
| PCT/FI2014/050518 WO2014207310A1 (fr) | 2013-06-25 | 2014-06-25 | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510251TA true SG11201510251TA (en) | 2016-01-28 |
Family
ID=51220584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510251TA SG11201510251TA (en) | 2013-06-25 | 2014-06-25 | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9663549B2 (fr) |
| EP (1) | EP3013846B1 (fr) |
| JP (1) | JP6556125B2 (fr) |
| KR (1) | KR20160042873A (fr) |
| CN (1) | CN105518015B (fr) |
| AR (1) | AR096729A1 (fr) |
| AU (1) | AU2014300894A1 (fr) |
| BR (1) | BR112015031846A8 (fr) |
| CA (1) | CA2914667A1 (fr) |
| EA (1) | EA201690077A1 (fr) |
| HK (1) | HK1217495A1 (fr) |
| IL (1) | IL242968A0 (fr) |
| MA (1) | MA38694B1 (fr) |
| MX (1) | MX2015017879A (fr) |
| SG (1) | SG11201510251TA (fr) |
| TN (1) | TN2015000555A1 (fr) |
| TW (1) | TW201534612A (fr) |
| WO (1) | WO2014207310A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016102776A1 (fr) * | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | Promédicaments d'inhibiteurs de la 17β-hsd1 |
| EP3237430B1 (fr) * | 2014-12-23 | 2019-03-20 | Forendo Pharma Ltd | PROMÉDICAMENTS D'INHIBITEURS DE 17ß -HSD1 |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| CA3066196C (fr) * | 2017-06-08 | 2023-08-29 | Forendo Pharma Ltd | Composes d'estradiol-1,3,5(10)-triene-one-17 du 15.s-[3-propanamido]-substitues et leurs 17-oximes pour utilisation dansl'inhibition de 17.s-hydroxysteroides deshydrogenases |
| BR112021010598A2 (pt) * | 2018-12-05 | 2021-08-24 | Forendo Pharma Ltd | Compostos, método para preparação de um composto e composição farmacêutica |
| CN114644673B (zh) * | 2020-12-19 | 2023-12-26 | 上海喀露蓝科技有限公司 | 一种雌二醇衍生物、其制备方法及其在医药上的用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999046279A2 (fr) | 1998-03-11 | 1999-09-16 | Endorecherche, Inc. | INHIBITEURS DE LA 17β-HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES |
| WO2000007996A2 (fr) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Modulateurs de recepteurs d'oestrogenes |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| AU2001288386B2 (en) * | 2000-11-27 | 2006-11-02 | Entremed, Inc. | 2-substituted estrogens as antiangiogenic agents |
| EP1423381B1 (fr) | 2001-09-06 | 2007-01-03 | Schering Corporation | Inhibiteurs de 17$g(b)-hydroxysteroide deshydrogenase de type 3 pour le traitement des maladies androgeno-dependantes |
| AR036812A1 (es) | 2001-10-17 | 2004-10-06 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes |
| US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| AR042046A1 (es) | 2002-11-18 | 2005-06-08 | Schering Corp | Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos |
| MXPA05006485A (es) | 2002-12-17 | 2005-08-26 | Schering Corp | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno. |
| WO2004085345A2 (fr) | 2003-03-21 | 2004-10-07 | Yale University | Esters d'acide carboxylique et d'estradiol substitues en 15$g(a) en tant qu'oestrogenes localement actifs |
| GB0306718D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| DE102004032673A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
| DE102004032674A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| AU2006251154B2 (en) | 2005-05-26 | 2012-06-28 | Solvay Pharmaceuticals Gmbh | 17beta-HSD1 and STS inhibitors |
| ES2424395T3 (es) | 2006-09-19 | 2013-10-01 | Abbott Products Gmbh | Derivados de estratrieno y sus usos como inhibidores de la 17-beta-hidroxiesteroide-deshidrogenasa |
| US8288367B2 (en) * | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| JP5264760B2 (ja) * | 2006-11-30 | 2013-08-14 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | １７β−ＨＳＤインヒビターとしての置換エストラトリエン誘導体 |
-
2014
- 2014-06-25 EP EP14742254.7A patent/EP3013846B1/fr active Active
- 2014-06-25 AR ARP140102399A patent/AR096729A1/es unknown
- 2014-06-25 MA MA38694A patent/MA38694B1/fr unknown
- 2014-06-25 SG SG11201510251TA patent/SG11201510251TA/en unknown
- 2014-06-25 CA CA2914667A patent/CA2914667A1/fr not_active Abandoned
- 2014-06-25 KR KR1020167001998A patent/KR20160042873A/ko not_active Application Discontinuation
- 2014-06-25 US US14/392,291 patent/US9663549B2/en active Active
- 2014-06-25 WO PCT/FI2014/050518 patent/WO2014207310A1/fr active Application Filing
- 2014-06-25 JP JP2016522679A patent/JP6556125B2/ja active Active
- 2014-06-25 MX MX2015017879A patent/MX2015017879A/es unknown
- 2014-06-25 BR BR112015031846A patent/BR112015031846A8/pt not_active IP Right Cessation
- 2014-06-25 AU AU2014300894A patent/AU2014300894A1/en not_active Abandoned
- 2014-06-25 EA EA201690077A patent/EA201690077A1/ru unknown
- 2014-06-25 TW TW103121874A patent/TW201534612A/zh unknown
- 2014-06-25 TN TN2015000555A patent/TN2015000555A1/en unknown
- 2014-06-25 CN CN201480046108.2A patent/CN105518015B/zh active Active
-
2015
- 2015-12-06 IL IL242968A patent/IL242968A0/en unknown
-
2016
- 2016-05-16 HK HK16105581.6A patent/HK1217495A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL242968A0 (en) | 2016-02-01 |
| TN2015000555A1 (en) | 2017-04-06 |
| CA2914667A1 (fr) | 2014-12-31 |
| HK1217495A1 (zh) | 2017-01-13 |
| US9663549B2 (en) | 2017-05-30 |
| WO2014207310A1 (fr) | 2014-12-31 |
| US20170081357A1 (en) | 2017-03-23 |
| CN105518015B (zh) | 2017-09-15 |
| EP3013846B1 (fr) | 2017-08-09 |
| KR20160042873A (ko) | 2016-04-20 |
| JP2016523886A (ja) | 2016-08-12 |
| CN105518015A (zh) | 2016-04-20 |
| MX2015017879A (es) | 2017-03-01 |
| BR112015031846A8 (pt) | 2018-03-06 |
| JP6556125B2 (ja) | 2019-08-07 |
| MA38694B1 (fr) | 2020-01-31 |
| BR112015031846A2 (pt) | 2017-07-25 |
| AU2014300894A1 (en) | 2016-01-28 |
| EA201690077A1 (ru) | 2016-09-30 |
| EP3013846A1 (fr) | 2016-05-04 |
| AR096729A1 (es) | 2016-01-27 |
| TW201534612A (zh) | 2015-09-16 |
| MA38694A2 (fr) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268340A (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
| IL263653A (en) | History of azabenzimidazole as PI3K inhibitors in the cell | |
| EP3030323A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3073999A4 (fr) | Forme cristalline i d'ibrutinib | |
| EP2981535B8 (fr) | Dérivés d'urée utilisés en tant qu'inhibiteurs de kinase | |
| TN2015000519A1 (en) | Small molecule inhibitors of fibrosis | |
| HK1217495A1 (zh) | 治療活性的作為 β-羥基類固醇脫氫酶抑制劑的 -氮取代雌三烯噻唑衍生物 | |
| HK1208378A1 (en) | Pharmaceutical composition for the treatment of fungal infections | |
| EP2961403A4 (fr) | Inhibiteurs hétérocycliques du canal sodique | |
| HK1258911A1 (zh) | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 | |
| ZA201604225B (en) | Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus | |
| HK1253572A1 (zh) | 作為tnap抑制劑的吡啶並噁嗪酮化合物 | |
| EP3037093A4 (fr) | Composition contenant un composé monoacétyldiacylglycérol comme principe actif pour la prévention ou le traitement de maladies pulmonaires obstructives chroniques | |
| EP3001814B8 (fr) | Formulations d'inhibiteur de xanthine oxydase | |
| HK1226072A1 (zh) | 作為bcl-3抑制劑的2-苯甲酰氨基苯甲酰胺衍生物 | |
| EP3024427A4 (fr) | Dérivés de 2,2,6-triméthylcyclohexane-carboxylate | |
| EP2965758A4 (fr) | Inhibiteur de la production d'ostéopontine comprenant un dérivé de dictyopyrone ou un dérivé de dihydrodictyopyrone en tant qu'ingrédient actif | |
| GB201518603D0 (en) | Therapeutically active compounds |